Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

2 Predictions for Novo Nordisk in 2026

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Novo Nordisk Is Selling Ozempic for $24 a Week in India. Why It’s So Cheap.

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...
Zacks Investment Research on MSN

NVO down 42% year to date: Is this an indication to sell the stock?

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk

Data from Structure Therapeutics and WAVE Life Sciences show that threats to Eli Lilly and Novo Nordisk’s dominance in weight ...
The Motley Fool

Why Novo Nordisk Stock Just Hit a 4-Year Low

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly. Novo Nordisk also lost a bidding war for a promising start-up. Novo Nordisk ...
Zacks Investment Research on MSN

NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes

Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...
Forbes

What's Happening With Novo Nordisk Stock?

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Wall Street Journal

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...
Investopedia

Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
AOL

Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in the weight-loss-drug market. U.S.-listed shares fell over 5% on Monday to a ...